TA178 Renal cell carcinoma: review decision - May 2012
TA Review of TA169; Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma and TA178; Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
The Institute was proposing that the guidance be transferred to the 'static guidance list'.
During consultation, the majority of comments received by the Institute agreed with the proposal put forward. After consideration of all of the comments (attached as appendix A), the Institute’s Guidance Executive has decided to proceed with the proposal. The guidance will now be transferred to the list of static appraisals.
This page was last updated: 25 May 2012